Skip to main content
Top
Published in: Ophthalmology and Therapy 3/2023

Open Access 18-03-2023 | Photodynamic Therapy | REVIEW

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

Authors: Claudio Iovino, Clemente Maria Iodice, Danila Pisani, Andrea Rosolia, Francesco Testa, Giuseppe Giannaccare, Jay Chhablani, Francesca Simonelli

Published in: Ophthalmology and Therapy | Issue 3/2023

Login to get access

Abstract

Yellow subthreshold micropulse laser (YSML) is a retinal laser capable of inducing a biologic response without causing thermal damage to the targeted tissue. The 577-nm YSML is delivered to the retina abiding by different protocols in which wavelength, power, duration, spot size and number of spots can be properly set to achieve the most effective and safe treatment response in various chorioretinal disorders. The ultrashort trains of power modulate the activation of the retinal pigment epithelium cells and intraretinal cells, such as Müller cells, causing no visible retinal scars. Subthreshold energy delivered by YSML stimulates the production of the heat-shock proteins, highly conserved molecules that protect cells against any sort of stress by blocking apoptotic and inflammatory pathways that cause cell damage. YSML treatment allows resorption of the subretinal fluid in central serous chorioretinopathy and intraretinal fluid in various conditions including diabetic macular edema, postoperative cystoid macular edema and other miscellaneous conditions. YSML also seems to modulate the development and progression of reticular pseudodrusen in dry age-related macular degeneration. The aim of this review is to discuss and summarize the safety and efficacy of YSML treatment in retinal diseases.
Literature
2.
go back to reference Molnar I, Poitry S, Tsacopoulos M, Gilodi N, Leuenberger PM. Effect of laser photocoagulation on oxygenation of the retina in miniature pigs. Invest Ophthalmol Vis Sci. 1985;26:1410–4.PubMed Molnar I, Poitry S, Tsacopoulos M, Gilodi N, Leuenberger PM. Effect of laser photocoagulation on oxygenation of the retina in miniature pigs. Invest Ophthalmol Vis Sci. 1985;26:1410–4.PubMed
3.
go back to reference Novack RL, Stefånsson E, Hatchell DL. The effect of photocoagulation on the oxygenation and ultrastructure of avascular retina. Exp Eye Res. 1990;50:289–96.PubMedCrossRef Novack RL, Stefånsson E, Hatchell DL. The effect of photocoagulation on the oxygenation and ultrastructure of avascular retina. Exp Eye Res. 1990;50:289–96.PubMedCrossRef
4.
go back to reference Mainster MA. Ophthalmic laser surgery: principles, technology, and technique. Trans New Orleans Acad Ophthalmol. 1985;33:81–101.PubMed Mainster MA. Ophthalmic laser surgery: principles, technology, and technique. Trans New Orleans Acad Ophthalmol. 1985;33:81–101.PubMed
5.
go back to reference Inagaki K, Shuo T, Katakura K, Ebihara N, Murakami A, Ohkoshi K. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells. J Ophthalmol. 2015;2015:729792.PubMedPubMedCentralCrossRef Inagaki K, Shuo T, Katakura K, Ebihara N, Murakami A, Ohkoshi K. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells. J Ophthalmol. 2015;2015:729792.PubMedPubMedCentralCrossRef
6.
go back to reference Brader HS, Young LHY. Subthreshold diode micropulse laser: a review. Semin Ophthalmol. 2016;31:30–9.PubMedCrossRef Brader HS, Young LHY. Subthreshold diode micropulse laser: a review. Semin Ophthalmol. 2016;31:30–9.PubMedCrossRef
7.
go back to reference Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14:19–26.PubMedCrossRef Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14:19–26.PubMedCrossRef
8.
go back to reference Sivaprasad S, Dorin G. Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Med Devices. 2012;9:189–97.PubMedCrossRef Sivaprasad S, Dorin G. Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Med Devices. 2012;9:189–97.PubMedCrossRef
9.
go back to reference Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker Dv. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017;37:1021–33.PubMedCrossRef Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker Dv. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017;37:1021–33.PubMedCrossRef
10.
go back to reference Stanga PE, Reck AC, Hamilton AMP. Micropulse laser in the treatment of diabetic macular edema. Semin Ophthalmol. 1999;14:210–3.PubMedCrossRef Stanga PE, Reck AC, Hamilton AMP. Micropulse laser in the treatment of diabetic macular edema. Semin Ophthalmol. 1999;14:210–3.PubMedCrossRef
11.
go back to reference Chhablani J, Chhablani J, Ong J, Rajendran A, Zhang X, Parolini B, et al. Subthreshold laser therapy guidelines for retinal diseases. Eye (Lond). 2022;12:1–2. Chhablani J, Chhablani J, Ong J, Rajendran A, Zhang X, Parolini B, et al. Subthreshold laser therapy guidelines for retinal diseases. Eye (Lond). 2022;12:1–2.
12.
go back to reference Lavinsky D, Wang J, Huie P, Dalal R, Lee SJ, Lee DY, et al. Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci. 2016;57:2488–500.PubMedPubMedCentralCrossRef Lavinsky D, Wang J, Huie P, Dalal R, Lee SJ, Lee DY, et al. Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci. 2016;57:2488–500.PubMedPubMedCentralCrossRef
13.
go back to reference Piri N, Kwong JMK, Gu L, Caprioli J. Heat shock proteins in the retina: focus on HSP70 and alpha crystallins in ganglion cell survival. Prog Retin Eye Res. 2016;52:22–46.PubMedPubMedCentralCrossRef Piri N, Kwong JMK, Gu L, Caprioli J. Heat shock proteins in the retina: focus on HSP70 and alpha crystallins in ganglion cell survival. Prog Retin Eye Res. 2016;52:22–46.PubMedPubMedCentralCrossRef
14.
go back to reference Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol. 2004;19:62–8.PubMedCrossRef Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol. 2004;19:62–8.PubMedCrossRef
15.
go back to reference Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H, Contag CH, et al. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci. 2011;52:1780–7.PubMedCrossRef Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H, Contag CH, et al. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci. 2011;52:1780–7.PubMedCrossRef
16.
go back to reference Lavinsky D, Cardillo JA, Melo LAS, Dare A, Farah ME, Belfort R. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:4314–23.PubMedCrossRef Lavinsky D, Cardillo JA, Melo LAS, Dare A, Farah ME, Belfort R. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:4314–23.PubMedCrossRef
18.
go back to reference Midena E, Bini S, Martini F, Enrica C, Pilotto E, Micera A, et al. Changes of aqueous humor müller cells’ biomarkers in human patients affected by diabetic macular edema after subthreshold micropulse laser treatment. Retina. 2020;40:126–34.PubMedCrossRef Midena E, Bini S, Martini F, Enrica C, Pilotto E, Micera A, et al. Changes of aqueous humor müller cells’ biomarkers in human patients affected by diabetic macular edema after subthreshold micropulse laser treatment. Retina. 2020;40:126–34.PubMedCrossRef
19.
go back to reference Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol. 2010;55:516–30.PubMedCrossRef Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol. 2010;55:516–30.PubMedCrossRef
20.
go back to reference Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, et al. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469–80.PubMedCrossRef Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, Danis RP, et al. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469–80.PubMedCrossRef
21.
go back to reference Striph GG, Hart WM, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology. 1988;95:1673–9.PubMedCrossRef Striph GG, Hart WM, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology. 1988;95:1673–9.PubMedCrossRef
22.
go back to reference Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, von Fricken MA, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503–11.PubMedCrossRef Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, von Fricken MA, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503–11.PubMedCrossRef
23.
go back to reference Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652–6.PubMedCrossRef Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652–6.PubMedCrossRef
25.
go back to reference Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93:1341–4.PubMedCrossRef Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93:1341–4.PubMedCrossRef
26.
go back to reference Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16.PubMedCrossRef Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16.PubMedCrossRef
28.
go back to reference Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274–84.PubMedPubMedCentralCrossRef Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274–84.PubMedPubMedCentralCrossRef
29.
go back to reference Citirik M. The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema. Lasers Med Sci. 2019;34:907–12.PubMedCrossRef Citirik M. The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema. Lasers Med Sci. 2019;34:907–12.PubMedCrossRef
30.
go back to reference Çitirik M. Non-damaging retinal laser therapy in recurrent diabetic macular edema after anti-VEGF injections. Turk J Med Sci. 2021;51:2616–20.PubMedCrossRef Çitirik M. Non-damaging retinal laser therapy in recurrent diabetic macular edema after anti-VEGF injections. Turk J Med Sci. 2021;51:2616–20.PubMedCrossRef
31.
go back to reference Donati MC, Murro V, Mucciolo DP, Giorgio D, Cinotti G, Virgili G, et al. Subthreshold yellow micropulse laser for treatment of diabetic macular edema: comparison between fixed and variable treatment regimen. Eur J Ophthalmol. 2021;31:1254–60.PubMedCrossRef Donati MC, Murro V, Mucciolo DP, Giorgio D, Cinotti G, Virgili G, et al. Subthreshold yellow micropulse laser for treatment of diabetic macular edema: comparison between fixed and variable treatment regimen. Eur J Ophthalmol. 2021;31:1254–60.PubMedCrossRef
35.
36.
go back to reference Kwon YH, Lee DK, Kwon OW. The short-term efficacy of subthreshold micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean J Ophthalmol. 2014;28:379–85.PubMedPubMedCentralCrossRef Kwon YH, Lee DK, Kwon OW. The short-term efficacy of subthreshold micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean J Ophthalmol. 2014;28:379–85.PubMedPubMedCentralCrossRef
37.
go back to reference Latalska M, Prokopiuk A, Wróbel-Dudzińska D, Mackiewicz J. Subthreshold micropulse yellow 577 nm laser therapy of diabetic macular oedema in rural and urban patients of south-eastern Poland. Ann Agric Environ Med. 2017;24:96–9.PubMedCrossRef Latalska M, Prokopiuk A, Wróbel-Dudzińska D, Mackiewicz J. Subthreshold micropulse yellow 577 nm laser therapy of diabetic macular oedema in rural and urban patients of south-eastern Poland. Ann Agric Environ Med. 2017;24:96–9.PubMedCrossRef
39.
go back to reference Valera-Cornejo DA, García-Roa M, Quiroz-Mendoza J, Arias-Gómez A, Ramírez-Neria P, Villalpando-Gómez Y, et al. Micropulse laser in patients with refractory and treatment-naïve center-involved diabetic macular edema: short terms visual and anatomic outcomes. Ther Adv Ophthalmol. 2021;13:251584142097911.CrossRef Valera-Cornejo DA, García-Roa M, Quiroz-Mendoza J, Arias-Gómez A, Ramírez-Neria P, Villalpando-Gómez Y, et al. Micropulse laser in patients with refractory and treatment-naïve center-involved diabetic macular edema: short terms visual and anatomic outcomes. Ther Adv Ophthalmol. 2021;13:251584142097911.CrossRef
40.
go back to reference Vujosevic S, Frizziero L, Martini F, Bini S, Convento E, Cavarzeran F, et al. Single retinal layer changes after subthreshold micropulse yellow laser in diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49:E218–25.PubMedCrossRef Vujosevic S, Frizziero L, Martini F, Bini S, Convento E, Cavarzeran F, et al. Single retinal layer changes after subthreshold micropulse yellow laser in diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49:E218–25.PubMedCrossRef
41.
go back to reference Vujosevic S, Toma C, Villani E, Brambilla M, Torti E, Leporati F, et al. Subthreshold micropulse laser in diabetic macular edema: 1-year improvement in OCT/OCT-angiography biomarkers. Transl Vis Sci Technol. 2020;9:31.PubMedPubMedCentralCrossRef Vujosevic S, Toma C, Villani E, Brambilla M, Torti E, Leporati F, et al. Subthreshold micropulse laser in diabetic macular edema: 1-year improvement in OCT/OCT-angiography biomarkers. Transl Vis Sci Technol. 2020;9:31.PubMedPubMedCentralCrossRef
42.
go back to reference Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Aqueous humor biomarkers of müller cell activation in diabetic eyes. Invest Ophthalmol Vis Sci. 2015;56:3913–8.PubMedCrossRef Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Aqueous humor biomarkers of müller cell activation in diabetic eyes. Invest Ophthalmol Vis Sci. 2015;56:3913–8.PubMedCrossRef
43.
go back to reference Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:74–80.PubMedPubMedCentralCrossRef Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:74–80.PubMedPubMedCentralCrossRef
44.
go back to reference Luttrull JK, Spink CJ. Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2006;37:370–7.PubMedCrossRef Luttrull JK, Spink CJ. Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2006;37:370–7.PubMedCrossRef
45.
go back to reference Vujosevic S, Martini F, Longhin E, Convento E, Cavarzeran F, Midena E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema. Retina. 2015;35:1594–603.PubMedCrossRef Vujosevic S, Martini F, Longhin E, Convento E, Cavarzeran F, Midena E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema. Retina. 2015;35:1594–603.PubMedCrossRef
46.
go back to reference Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014;34:87–97.PubMedCrossRef Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014;34:87–97.PubMedCrossRef
47.
go back to reference Wells-Gray EM, Doble N, Ohr MP, Choi SS. Structural integrity of individual cone photoreceptors after short-wavelength subthreshold micropulse laser therapy for diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49:946–54.PubMedPubMedCentralCrossRef Wells-Gray EM, Doble N, Ohr MP, Choi SS. Structural integrity of individual cone photoreceptors after short-wavelength subthreshold micropulse laser therapy for diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2018;49:946–54.PubMedPubMedCentralCrossRef
48.
go back to reference Vujosevic S, Gatti V, Muraca A, Brambilla M, Villani E, Nucci P, et al. Optical coherence tomography angiography changes after subthreshold micropulse yellow laser in diabetic macular edema. Retina. 2020;40(2):312–21.PubMedCrossRef Vujosevic S, Gatti V, Muraca A, Brambilla M, Villani E, Nucci P, et al. Optical coherence tomography angiography changes after subthreshold micropulse yellow laser in diabetic macular edema. Retina. 2020;40(2):312–21.PubMedCrossRef
49.
go back to reference Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond). 2002;16:242–60.PubMedCrossRef Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye (Lond). 2002;16:242–60.PubMedCrossRef
50.
51.
go back to reference Maltsev DS, Kulikov AN, Burnasheva MA, Kazak AA, Chhablani J. Structural en face optical coherence tomography imaging for identification of leaky microaneurysms in diabetic macular edema. Int Ophthalmol. 2020;40:787–94.PubMedCrossRef Maltsev DS, Kulikov AN, Burnasheva MA, Kazak AA, Chhablani J. Structural en face optical coherence tomography imaging for identification of leaky microaneurysms in diabetic macular edema. Int Ophthalmol. 2020;40:787–94.PubMedCrossRef
52.
go back to reference Sarthy V. Focus on molecules: glial fibrillary acidic protein (GFAP). Exp Eye Res. 2007;84:381–2.PubMedCrossRef Sarthy V. Focus on molecules: glial fibrillary acidic protein (GFAP). Exp Eye Res. 2007;84:381–2.PubMedCrossRef
54.
go back to reference Jaki Mekjavić P, Balčiūnienė VJ, Ćeklić L, Ernest J, Jamrichova Z, Nagy ZZ, et al. The burden of macular diseases in central and eastern Europe-implications for healthcare systems. Value Health Reg Issues. 2019;19:1–6.PubMedCrossRef Jaki Mekjavić P, Balčiūnienė VJ, Ćeklić L, Ernest J, Jamrichova Z, Nagy ZZ, et al. The burden of macular diseases in central and eastern Europe-implications for healthcare systems. Value Health Reg Issues. 2019;19:1–6.PubMedCrossRef
55.
go back to reference Akkaya S, Açikalin B, Dogan YE, Çoban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020;13:1606–11.PubMedPubMedCentralCrossRef Akkaya S, Açikalin B, Dogan YE, Çoban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020;13:1606–11.PubMedPubMedCentralCrossRef
56.
go back to reference Altınel MG, Acikalin B, Alis MG, Demir G, Mutibayraktaroglu KM, Totuk OMG, et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema. Lasers Med Sci. 2021;36:1545–53.PubMedCrossRef Altınel MG, Acikalin B, Alis MG, Demir G, Mutibayraktaroglu KM, Totuk OMG, et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema. Lasers Med Sci. 2021;36:1545–53.PubMedCrossRef
57.
go back to reference Ecsedy M, Kovács I, Gergely R, Gombos K, Meisel J, Kovács A, et al. First experiences with Navilas® 577s micropulse laser in the treatment of diabetic maculopathy. Orv Hetil. 2020;161:2078–85.PubMedCrossRef Ecsedy M, Kovács I, Gergely R, Gombos K, Meisel J, Kovács A, et al. First experiences with Navilas® 577s micropulse laser in the treatment of diabetic maculopathy. Orv Hetil. 2020;161:2078–85.PubMedCrossRef
58.
go back to reference el Matri L, Chebil A, el Matri K, Falfoul Y, Chebbi Z. Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up. Ther Adv Ophthalmol. 2021;13:251584142110408.CrossRef el Matri L, Chebil A, el Matri K, Falfoul Y, Chebbi Z. Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up. Ther Adv Ophthalmol. 2021;13:251584142110408.CrossRef
59.
go back to reference Elhamid AHA. Combined intravitreal dexamethasone implant and micropulse yellow laser for treatment of anti-VEGF resistant diabetic macular edema. Open Ophthalmol J. 2017;11:164–72.PubMedPubMedCentralCrossRef Elhamid AHA. Combined intravitreal dexamethasone implant and micropulse yellow laser for treatment of anti-VEGF resistant diabetic macular edema. Open Ophthalmol J. 2017;11:164–72.PubMedPubMedCentralCrossRef
60.
go back to reference Kanar H, Arsan A, Altun A, Aki S, Hacisalihoglu A. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol. 2020;68:145–51.PubMedCrossRef Kanar H, Arsan A, Altun A, Aki S, Hacisalihoglu A. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol. 2020;68:145–51.PubMedCrossRef
61.
go back to reference Khattab AM, Hagras SM, AbdElhamid AH, Torky MA, Awad EA, Abdelhameed AG. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:1373–80.CrossRef Khattab AM, Hagras SM, AbdElhamid AH, Torky MA, Awad EA, Abdelhameed AG. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:1373–80.CrossRef
62.
go back to reference Lai FHP, Chan RPS, Lai ACH, Tsang S, Woo TTY, Lam RF, et al. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema. Jpn J Ophthalmol. 2021;65:680–8.PubMedCrossRef Lai FHP, Chan RPS, Lai ACH, Tsang S, Woo TTY, Lam RF, et al. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema. Jpn J Ophthalmol. 2021;65:680–8.PubMedCrossRef
63.
go back to reference Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol. 2018;28:68–73.PubMedCrossRef Moisseiev E, Abbassi S, Thinda S, Yoon J, Yiu G, Morse LS. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema. Eur J Ophthalmol. 2018;28:68–73.PubMedCrossRef
68.
go back to reference Li ZJ, Xiao JH, Zeng P, Zeng R, Gao X, Zhang YC, et al. Optical coherence tomography angiography assessment of 577 nm laser effect on severe non-proliferative diabetic retinopathy with diabetic macular edema. Int J Ophthalmol. 2020;13:1257–65.PubMedPubMedCentralCrossRef Li ZJ, Xiao JH, Zeng P, Zeng R, Gao X, Zhang YC, et al. Optical coherence tomography angiography assessment of 577 nm laser effect on severe non-proliferative diabetic retinopathy with diabetic macular edema. Int J Ophthalmol. 2020;13:1257–65.PubMedPubMedCentralCrossRef
71.
go back to reference Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F. Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res. 2015;55:76–83.PubMedCrossRef Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F. Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res. 2015;55:76–83.PubMedCrossRef
72.
go back to reference Parodi MB, Arrigo A, Iacono P, Falcomatà B, Bandello F. Central serous chorioretinopathy: treatment with laser. Pharmaceuticals (Basel). 2020;13:1–15. Parodi MB, Arrigo A, Iacono P, Falcomatà B, Bandello F. Central serous chorioretinopathy: treatment with laser. Pharmaceuticals (Basel). 2020;13:1–15.
73.
go back to reference Ambiya V, Goud A, Mathai A, Rani PK, Chhablani J. Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy. Dove Med Press Ltd. 2016;10:1513–9. Ambiya V, Goud A, Mathai A, Rani PK, Chhablani J. Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy. Dove Med Press Ltd. 2016;10:1513–9.
74.
go back to reference Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (Lond). 2018;32:726–33.PubMedCrossRef Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (Lond). 2018;32:726–33.PubMedCrossRef
75.
go back to reference Chhablani J, Kalra G, Alkwatli L, Fassbender B, Amoroso F, Chandra K, et al. Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy. Int J Retina Vitreous. 2021;7:62.PubMedPubMedCentralCrossRef Chhablani J, Kalra G, Alkwatli L, Fassbender B, Amoroso F, Chandra K, et al. Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy. Int J Retina Vitreous. 2021;7:62.PubMedPubMedCentralCrossRef
76.
go back to reference Elhamid AHA. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2277–83. Elhamid AHA. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2277–83.
78.
go back to reference Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Grzybowski A. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Graefe’s Arch Clin Exp Ophthalmol. 2017;255:2299–306.CrossRef Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Grzybowski A. Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser. Graefe’s Arch Clin Exp Ophthalmol. 2017;255:2299–306.CrossRef
79.
go back to reference Işık MU, Değirmenci MFK, Sağlık A. Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy. Int J Ophthalmol. 2020;13:1404–10.PubMedPubMedCentralCrossRef Işık MU, Değirmenci MFK, Sağlık A. Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy. Int J Ophthalmol. 2020;13:1404–10.PubMedPubMedCentralCrossRef
80.
go back to reference Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2015;253:2129–35.CrossRef Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2015;253:2129–35.CrossRef
81.
go back to reference Kim YJ, Kim SY, Ha S, Moon D, Seong S, Kwon OW, et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. Eye (Lond). 2019;33:819–25.PubMedCrossRef Kim YJ, Kim SY, Ha S, Moon D, Seong S, Kwon OW, et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. Eye (Lond). 2019;33:819–25.PubMedCrossRef
82.
go back to reference Kiraly P, Smrekar J, Jaki MP. Morphological parameters predicting subthreshold micropulse laser effectiveness in central serous chorioretinopathy. Lasers Med Sci. 2022;37(8):3129–36.PubMedCrossRef Kiraly P, Smrekar J, Jaki MP. Morphological parameters predicting subthreshold micropulse laser effectiveness in central serous chorioretinopathy. Lasers Med Sci. 2022;37(8):3129–36.PubMedCrossRef
85.
go back to reference Scholz P, Ersoy L, Boon CJF, Fauser S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica. 2015;234:189–94.PubMedCrossRef Scholz P, Ersoy L, Boon CJF, Fauser S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica. 2015;234:189–94.PubMedCrossRef
86.
go back to reference Schworm B, Siedlecki J, Keidel LF, Herold TR, Luft N, Priglinger SG. Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259:3271–81.PubMedPubMedCentralCrossRef Schworm B, Siedlecki J, Keidel LF, Herold TR, Luft N, Priglinger SG. Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259:3271–81.PubMedPubMedCentralCrossRef
87.
go back to reference Uzlu D, Erdöl H, Kola M, Özbay AD. The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36:981–8.PubMedCrossRef Uzlu D, Erdöl H, Kola M, Özbay AD. The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36:981–8.PubMedCrossRef
88.
go back to reference Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Basingstoke). 2015;29:258–65. Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Basingstoke). 2015;29:258–65.
90.
go back to reference Zhou L, Chong V, Lai K, Huang C, Xu F, Gong Y, et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. Lasers Med Sci. 2019;34:1345–51.PubMedCrossRef Zhou L, Chong V, Lai K, Huang C, Xu F, Gong Y, et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. Lasers Med Sci. 2019;34:1345–51.PubMedCrossRef
92.
go back to reference Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Turkmen OF. Comparison of the efficacy and safety between subthreshold micropulse laser, standard-fluence and low-fluence photodynamic therapy for chronic central serous chorioretinopathy. J Fr Ophtalmol. 2021;44:499–508.PubMedCrossRef Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Turkmen OF. Comparison of the efficacy and safety between subthreshold micropulse laser, standard-fluence and low-fluence photodynamic therapy for chronic central serous chorioretinopathy. J Fr Ophtalmol. 2021;44:499–508.PubMedCrossRef
93.
go back to reference Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115:2229–34.PubMedCrossRef Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115:2229–34.PubMedCrossRef
94.
go back to reference Altınel MG, Acikalin B, Gunes H, Demir G. Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36:1505–14.PubMedCrossRef Altınel MG, Acikalin B, Gunes H, Demir G. Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36:1505–14.PubMedCrossRef
95.
go back to reference Zhou L, Li T, Lai K, Huang C, Xu F, Zhu Z, et al. Subretinal fibrin absorption after 577-nm subthreshold micropulse laser therapy in a CSC case: a brief report. Lasers Med Sci. 2018;33:1175–8.PubMedCrossRef Zhou L, Li T, Lai K, Huang C, Xu F, Zhu Z, et al. Subretinal fibrin absorption after 577-nm subthreshold micropulse laser therapy in a CSC case: a brief report. Lasers Med Sci. 2018;33:1175–8.PubMedCrossRef
96.
go back to reference van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125:1547–55.PubMedCrossRef van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125:1547–55.PubMedCrossRef
97.
go back to reference Wu Z, Wang H, An J. Comparison of the efficacy and safety of subthreshold micropulse laser with photodynamic therapy for the treatment of chronic central serous chorioretinopathy: a meta-analysis. Medicine (Baltimore). 2021;100:e25722.PubMedCrossRef Wu Z, Wang H, An J. Comparison of the efficacy and safety of subthreshold micropulse laser with photodynamic therapy for the treatment of chronic central serous chorioretinopathy: a meta-analysis. Medicine (Baltimore). 2021;100:e25722.PubMedCrossRef
99.
go back to reference Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, et al. Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. Am J Ophthalmol. 2020;217:104–13.PubMedCrossRef Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, et al. Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. Am J Ophthalmol. 2020;217:104–13.PubMedCrossRef
100.
go back to reference Roca JA, Wu L, Fromow-Guerra J, Rodríguez FJ, Berrocal MH, Rojas S, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018;102:1696–700.PubMedCrossRef Roca JA, Wu L, Fromow-Guerra J, Rodríguez FJ, Berrocal MH, Rojas S, et al. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. Br J Ophthalmol. 2018;102:1696–700.PubMedCrossRef
101.
go back to reference Ntomoka CG, Rajesh B, Muriithi GM, Goud A, Chhablani J. Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy. Eye (Lond). 2018;32:1079–86.PubMedCrossRef Ntomoka CG, Rajesh B, Muriithi GM, Goud A, Chhablani J. Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy. Eye (Lond). 2018;32:1079–86.PubMedCrossRef
102.
go back to reference Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Basingstoke). 2016;30:1371–7. Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Basingstoke). 2016;30:1371–7.
104.
go back to reference Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol. 2021;105:555–60.PubMedCrossRef Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol. 2021;105:555–60.PubMedCrossRef
105.
go back to reference van Rijssen TJ, Singh SR, van Dijk EHC, Rasheed MA, Vupparaboina KK, Boon CJF, et al. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:1191–7.PubMedPubMedCentralCrossRef van Rijssen TJ, Singh SR, van Dijk EHC, Rasheed MA, Vupparaboina KK, Boon CJF, et al. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:1191–7.PubMedPubMedCentralCrossRef
106.
go back to reference Sun Z, Huang Y, Nie C, Wang Z, Pei J, Lin B, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond). 2020;34:1592–9.PubMedCrossRef Sun Z, Huang Y, Nie C, Wang Z, Pei J, Lin B, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond). 2020;34:1592–9.PubMedCrossRef
108.
go back to reference Iacono P, Toto L, Costanzo E, Varano M, Parravano MC. Pharmacotherapy of central serous chorioretinopathy: a review of the current treatments. Curr Pharm Des. 2018;24:4864–73.PubMedCrossRef Iacono P, Toto L, Costanzo E, Varano M, Parravano MC. Pharmacotherapy of central serous chorioretinopathy: a review of the current treatments. Curr Pharm Des. 2018;24:4864–73.PubMedCrossRef
109.
go back to reference Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.PubMedCrossRef Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.PubMedCrossRef
111.
go back to reference Vignesh TP, Maitray A, Sen S, Chakrabarti A, Kannan NB, Ramasamy K. Subthreshold micro-pulse yellow laser and eplerenone drug therapy in chronic central serous chorio-retinopathy patients: a comparative study. Semin Ophthalmol. 2020;35:237–45.PubMedCrossRef Vignesh TP, Maitray A, Sen S, Chakrabarti A, Kannan NB, Ramasamy K. Subthreshold micro-pulse yellow laser and eplerenone drug therapy in chronic central serous chorio-retinopathy patients: a comparative study. Semin Ophthalmol. 2020;35:237–45.PubMedCrossRef
112.
go back to reference Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRef Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMedCrossRef
113.
go back to reference Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A review of current and future management of geographic atrophy. Ophthalmol Ther. 2017;6:69–77.PubMedPubMedCentralCrossRef Sacconi R, Corbelli E, Querques L, Bandello F, Querques G. A review of current and future management of geographic atrophy. Ophthalmol Ther. 2017;6:69–77.PubMedPubMedCentralCrossRef
114.
go back to reference Querques G, Querques L, Martinelli D, Massamba N, Coscas G, Soubrane G, et al. Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration. Retina. 2011;31:518–26.PubMedCrossRef Querques G, Querques L, Martinelli D, Massamba N, Coscas G, Soubrane G, et al. Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration. Retina. 2011;31:518–26.PubMedCrossRef
116.
go back to reference Luttrull JK, Chang DB, Margolis BWL, Dorin G, Luttrull DK. Laser resensitization of medically unresponsive neovascular age-related macular degeneration: efficacy and Implications. Retina. 2015;35:1184–94.PubMedCrossRef Luttrull JK, Chang DB, Margolis BWL, Dorin G, Luttrull DK. Laser resensitization of medically unresponsive neovascular age-related macular degeneration: efficacy and Implications. Retina. 2015;35:1184–94.PubMedCrossRef
118.
go back to reference Querques G, Sacconi R, Gelormini F, Borrelli E, Prascina F, Zucchiatti I, et al. Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration. Sci Rep. 2021;11:2193.PubMedPubMedCentralCrossRef Querques G, Sacconi R, Gelormini F, Borrelli E, Prascina F, Zucchiatti I, et al. Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration. Sci Rep. 2021;11:2193.PubMedPubMedCentralCrossRef
119.
go back to reference Huang Z, Deng KY, Deng YM, Hui YN, Song YP. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study. Int J Ophthalmol. 2022;15:474–82.PubMedPubMedCentralCrossRef Huang Z, Deng KY, Deng YM, Hui YN, Song YP. Long-term outcomes of drusenoid pigment epithelium detachment in intermediate AMD treated with 577 nm subthreshold micropulse laser: a preliminary clinical study. Int J Ophthalmol. 2022;15:474–82.PubMedPubMedCentralCrossRef
120.
go back to reference Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557.PubMedPubMedCentral Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557.PubMedPubMedCentral
121.
go back to reference Erichev VP, Kozlova IV, Kosova JV. Frequency and type of macular edema after cataract surgery in patients with glaucoma. Vestn Oftalmol. 2019;135:241–7.PubMedCrossRef Erichev VP, Kozlova IV, Kosova JV. Frequency and type of macular edema after cataract surgery in patients with glaucoma. Vestn Oftalmol. 2019;135:241–7.PubMedCrossRef
124.
go back to reference Demirel S, Batioǧlu F, Özmert E. Intravitreal ranibizumab for the treatment of cystoid macular edema in irvine-gass syndrome. J Ocul Pharmacol Ther. 2012;28:636–9.PubMedCrossRef Demirel S, Batioǧlu F, Özmert E. Intravitreal ranibizumab for the treatment of cystoid macular edema in irvine-gass syndrome. J Ocul Pharmacol Ther. 2012;28:636–9.PubMedCrossRef
125.
go back to reference Verdina T, Ferrari C, Valerio E, Brombin A, Lazzerini A, Mastropasqua R, et al. Subthreshold micropulse yellow laser for the management of refractory cystoid macular edema consequent to complicated cataract surgery. Eur J Ophthalmol. 2021;31:NP93-8.PubMedCrossRef Verdina T, Ferrari C, Valerio E, Brombin A, Lazzerini A, Mastropasqua R, et al. Subthreshold micropulse yellow laser for the management of refractory cystoid macular edema consequent to complicated cataract surgery. Eur J Ophthalmol. 2021;31:NP93-8.PubMedCrossRef
127.
go back to reference Giuliari GP, Sadaka A, Hinkle DM, Simpson ER. Current treatments for radiation retinopathy. Acta Oncol. 2011;50:6–13.PubMedCrossRef Giuliari GP, Sadaka A, Hinkle DM, Simpson ER. Current treatments for radiation retinopathy. Acta Oncol. 2011;50:6–13.PubMedCrossRef
128.
go back to reference Wong JG, Nguyen TTH. Yellow pattern 577-nm micropulse laser: treatment of macular edema from radiation retinopathy—a case report. Case Rep Ophthalmol. 2017;8:81–6.PubMedPubMedCentralCrossRef Wong JG, Nguyen TTH. Yellow pattern 577-nm micropulse laser: treatment of macular edema from radiation retinopathy—a case report. Case Rep Ophthalmol. 2017;8:81–6.PubMedPubMedCentralCrossRef
129.
go back to reference Chatziralli IP, Jaulim A, Peponis VG, Mitropoulos PG, Moschos MM. Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol. 2014;29:85–107.PubMedCrossRef Chatziralli IP, Jaulim A, Peponis VG, Mitropoulos PG, Moschos MM. Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol. 2014;29:85–107.PubMedCrossRef
130.
go back to reference Terashima H, Hasebe H, Okamoto F, Matsuoka N, Sato Y, Fukuchi T. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result. Retina. 2019;39:1377–84.PubMedCrossRef Terashima H, Hasebe H, Okamoto F, Matsuoka N, Sato Y, Fukuchi T. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result. Retina. 2019;39:1377–84.PubMedCrossRef
131.
go back to reference Yannuzzi LA, Bardal AMC, Freund, Bailey K, Chen K-J, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124(4):450–60.PubMedCrossRef Yannuzzi LA, Bardal AMC, Freund, Bailey K, Chen K-J, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124(4):450–60.PubMedCrossRef
132.
133.
go back to reference Kang YK, Park HS. Subthreshold micropulse yellow laser (577 nm) for idiopathic macular telangiectasia type 1 resistant to intravitreal injection. Korean J Ophthalmol. 2020;34(2):168–9.PubMedPubMedCentralCrossRef Kang YK, Park HS. Subthreshold micropulse yellow laser (577 nm) for idiopathic macular telangiectasia type 1 resistant to intravitreal injection. Korean J Ophthalmol. 2020;34(2):168–9.PubMedPubMedCentralCrossRef
Metadata
Title
Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature
Authors
Claudio Iovino
Clemente Maria Iodice
Danila Pisani
Andrea Rosolia
Francesco Testa
Giuseppe Giannaccare
Jay Chhablani
Francesca Simonelli
Publication date
18-03-2023
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 3/2023
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-023-00698-w

Other articles of this Issue 3/2023

Ophthalmology and Therapy 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare